NCT03861247 is a Phase 3 clinical trial of Phosphate-binder intervention in Maintenance Hemodialysis, sponsored by Chen Jing.

Who is sponsoring NCT03861247?

NCT03861247 is sponsored by Chen Jing.

What drugs are being tested in NCT03861247?

Interventions in NCT03861247: Phosphate-binder intervention, Phosphorus-restricted dietary intervention.

What condition does NCT03861247 study?

NCT03861247 studies Maintenance Hemodialysis, Hyperphosphatemia.

Is NCT03861247 still recruiting?

NCT03861247 is currently completed. Last updated 31 August 2021.

Last reviewed 2021-08-31 · How we verify

NCT03861247

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients

Completed Phase 3 Last updated 31 August 2021

What this trial tests

Phase 3 trial testing Phosphate-binder intervention in Maintenance Hemodialysis in 123 participants. Completed in 15 April 2021.

Timeline

29 November 2019

Primary endpoint
3 January 2021

15 April 2021

Quick facts

Lead sponsor	Chen Jing
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	123
Start date	29 November 2019
Primary completion	3 January 2021
Estimated completion	15 April 2021
Sites	2 locations across China

Drugs / interventions tested

Phosphate-binder intervention — full drug profile →
Phosphorus-restricted dietary intervention

Conditions studied

Maintenance Hemodialysis — all drugs for Maintenance Hemodialysis →
Hyperphosphatemia — all drugs for Hyperphosphatemia →

Sponsor

Chen Jing — full company profile →

Who can join

Adults 18 to 85, any sex, with Maintenance Hemodialysis or Hyperphosphatemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research is designed as a prospective, randomized, controlled clinical trial without blinding. A total of 116 participants with hyperphosphatemia will be enrolled from three hemodialysis center (56 from Huashan Hospital, 30 from Huadong Hospital and 30 from Tongji Hospital). All participants will be randomly divided into control group and intervention group in a ratio of 1:1. Phosphorus balance status is evaluated in participants of the intervention group by the phosphorus balance calculator. Then, these participants will be given individualized phosphate-binders, dietary and dialysis intervention according to the results of phosphorus balance evaluation. Participants in the control group will not receive the phosphorus balance status evaluation but receive phosphate-binder treatment according to the KDIGO Guidelines. Dietary phosphorus intake, dialysate calcium concentration and dose of active vitamin D, phosphorus-binders of all participants will be recorded during the whole research program. After two-week treatment, the phosphorus balance of participants in intervention group will be evaluated again and the therapeutic strategies then will be adjusted. At the same time, the therapeutic strategies of participants in the control group will be adjusted according to the serum phosphorus concentration. All participants will be followed up for two weeks again and receive blood test and related examinations at the end of study. The results of final examinations will be analyzed to evaluate the efficacy of individualized treatment of hyperphosphatemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Maintenance Hemodialysis

Currently open trials in the same condition.

NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
NCT07291154 — Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy · NA · recruiting

Other Chen Jing trials

Trials by the same sponsor.

NCT07361783 — Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03861247 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chen Jing
Last refreshed: 31 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03861247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing